N-ACETYL CYSTEINE COMPOSITIONS IN THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS

摘要

The described invention provides a method and kit for treating a lupus condition with N- acetyl-L-cysteine (NAC) compositions that improve lupus disease activity driven by a decrease in the activity of the mammalian target of rapamycin (mTOR). The compositions of the described invention is effective to: (1) reduce fatigue; (2) reduce cognitive/inattentive component of attention deficit and hyperactivity (ADHD) self-report scale (ASRS); (3) reduce inflammation, for example, as measured by the systemic lupus erythematosus disease activity index (SLEDAI), and the British Isles Lupus Assessment Group (BILAG) score; (4) modulate mitochondrial potential and (5) reduce T cell cycle dysfunction driven by a decrease in the activity of the mammalian target of rapamycin (mTOR) in patients suffering from systemic lupus erythematosus (SLE).